Although most malignant tumors are epithelia-derived carcinomas, methods for specific and effective delivery of antitumor agents to carcinomas have not been developed. Recent reports indicate that epithelia overexpress claudin-3 and -
of Pseudomonas exotoxin. This fusion protein, C-CPE-PSIF, was cytotoxic to MCF-7 human breast cancer cells, which express endogenous claudin-4, but it was not toxic to mouse fibroblast L cells, which lack endogenous claudin-4. The cytotoxicity of C-CPE-PSIF was attenuated by pretreating the MCF-7 cells with C-CPE but not bovine serum albumin. Also, deletion of the claudin-4-binding region of C-CPE reduced the cytotoxicity of C-CPE-PSIF. Finally, we found that C-CPE-PSIF is toxic to L cells expressing claudin-4 but not to normal L cells or cells expressing claudin-1, -2, or -5. These results indicate that use of the C-CPE peptide may provide a novel way to target drugs to claudin-expressing cells.
Epithelial-derived tumors account for 90% of all malignant tumors, and their resistance to chemotherapy is a major clinical problem (Greenlee et al., 2000) . Recent progress in combinatorial chemistry, proteomics, and genomics research has further advanced the development of effective drugs against carcinomas, but, for clinical application, it is also essential to develop selective and efficient drug delivery systems for these novel drugs (Allen and Cullis, 2004) .
These drugs can be delivered by targeting several cell surface molecules, including carcinoembryonal antigen, carboanhydrage IX, and epithelial cell adhesion molecule (Steffens et al., 1997; Chester et al., 2000; Mayer et al., 2000; McLaughlin et al., 2001) . In fact, experimental therapies have been developed using antibody-mediated targeting of these molecules. However, because carcinoembryonal antigen and carboanhydrage IX are expressed by carcinomas as well as normal epithelium in kidney and liver, side effects are difficult to avoid (Steffens et al., 1997; Chester et al., 2000; Mayer et al., 2000) . Moreover, the antibody for epithelial cell adhesion molecule itself is toxic to normal epithelium (McLaughlin et al., 2001) .
Tight junctions (TJs), which are points of intercellular contact and interaction, are characteristic and complex structures in the epithelia. TJs play a critical role in forming a barrier between apical and basal sides of the cell, and they are present on the lateral side of the cell where they mediate intercellular interactions (Schneeberger and Lynch, 2004) . Loss of polarity is a typical feature of transformation in epithelial cells. Furthermore, abnormal localization of membrane proteins, including TJ components, adherence junction proteins, and apical and basal proteins, is observed during carcinogenesis (Wodarz, 2000; Yarden and Sliwkowski, 2001; Vermeer et al., 2003) . These findings indicate that abnor-mally localized membrane proteins may be useful for targeting drugs to carcinoma cells.
Claudin is an approximately 23-kDa transmembrane protein found in the TJ, and it plays a pivotal role in the barrier function of the TJ . There are more than 20 members of claudin family, and they are expressed in a tissue-specific manner (Morita et al., 1999a,b) . For instance, claudin-1 is ubiquitously expressed, and claudin-3 is observed in the lung and liver. In mice, claudin-5 is expressed in all blood endothelial cells. Claudin-6 is widely expressed only in the fetus. Interestingly, the overexpression of claudins is frequently observed in the epithelium of ovarian cancer, hepatocellular carcinoma, malignant pancreatic cancer, and prostate cancer (Hough et al., 2000; Long et al., 2001; Michl et al., 2003; Rangel et al., 2003; Cheung et al., 2005) . Therefore, claudins are promising candidates for the targeting of anticancer drugs to carcinoma cells.
Clostridium perfringens enterotoxin (CPE) is a single polypeptide with a molecular mass of 35 kDa that causes food poisoning associated with most human food-borne illnesses (McClane and Chakrabarti, 2004) . CPE is made up of two functionally distinct domains: an approximately 22-kDa Nterminal domain that mediates cytotoxicity and an approximately 13-kDa C-terminal domain (C-CPE) that mediates binding (McClane and Chakrabarti, 2004) . Claudin-3 and -4 are the receptors for CPE (Katahira et al., 1997; Sonoda et al., 1999) , and we and others have shown that they bind to CPE via the C-CPE domain (Katahira et al., 1997; Sonoda et al., 1999; Fujita et al., 2000; Kondoh et al., 2005) . These findings suggest that CPE could be used for the targeting of claudins on epithelial carcinoma cells. Indeed, CPE has been successfully used to treat human ovarian and pancreatic cancers, both of which express high levels of claudin-3 or -4 (Michl et al., 2001; Santin et al., 2005) .
In the present study, we investigated whether C-CPE can be used to target claudin-4-expressing cells. For this purpose, we utilized a PSIF derived from PE as a reporter molecule (Leamon et al., 1993; Mesri et al., 1994; Beers et al., 2000) to assess targeting of claudin-4-expressing cells. PE (GenBank accession no. K01397; http://www.ncbi.nlm.nih.gov/entrez/ viewer.fcgi?dbϭnucleotide&valϭ151215) binds to the cell surface and is internalized via the endocytotic pathway, after which it escapes from endosomes into the cytosol. The PE fragments (PSIF) released into the cytosol inhibit protein synthesis by blocking the function of elongation factor 2 (Ogata et al., 1990) . The PSIF, which cannot invade into cells, does not show any cytotoxicity because of lacking the cell binding domain. We show here that a C-CPE-PSIF fusion was toxic to cells expressing claudin-4 but not to cells expressing claudin-1. In addition, the cytotoxic effects of C-CPE-PSIF were dose dependently attenuated by C-CPE. Thus, C-CPE is a potent molecule for targeting of claudin-4-expressing cells and should be useful as a system for delivering drugs against malignant carcinomas.
Materials and Methods
Chemicals. Anti-FLAG M2 affinity gel, anti-FLAG M2 monoclonal antibody-peroxidase conjugate, FLAG peptide, and bovine serum albumin (BSA) were purchased from Sigma-Aldrich (St. Louis, MO). Glutathione-Sepharose 4B resin, thrombin protease, and Benzamidine-Sepharose 4 Fast Flow were obtained from GE Healthcare (Little Chalfont, Buckinghamshire, UK). Horseradish peroxidaselabeled Ab, anti-claudin-1 pAb, anti-claudin-2 pAb, anti-claudin-4 mAb, anti-claudin-5 mAb, and anti ␤-actin mAb were obtained from Zymed Laboratories (South San Francisco, CA). All other reagents used were research grade.
Cell Culture. Human breast cancer cell line MCF-7 cells and human intestinal cell line Caco-2 cells were maintained in RPMI 1640 medium and Dulbecco's modified Eagle's medium containing 10% fetal calf serum at 37°C, respectively. Mouse fibroblast cell line L cells and mouse claudin-expressing L cells, kindly provided by Dr. S. Tsukita (Kyoto University, Japan) (Morita et al., 1999b; Sonoda et al., 1999) , were cultured in modified Eagle's medium containing 10% fetal calf serum at 37°C.
Preparation of C-CPE-PSIF Fusions. The plasmids containing fusions of PSIF with C-CPE and C-CPE lacking its C-terminal 30 amino acids (C-CPE289) were prepared as follows. C-CPE and C-CPE289 were amplified by polymerase chain reaction (PCR) using pET16bHis 10 C-CPE as a template (Katahira et al., 1997) , a common forward primer (5Ј-CCATGGCCGAGAGATGTGTTTTAACAGTT-3Ј, NcoI site is underlined), and a reverse primer for C-CPE (5Ј-GCG-GCCGCAAATTTTTGAAATAATATTGA-3Ј, NotI site is underlined) or C-CPE289 (5Ј-GCGGCCGCTATATCAACATAATGATCTTT-3Ј, NotI site is underlined). The resulting PCR fragments were subcloned into the pGEM T-Easy Vector to create pTA/C-CPE and pTA/C-CPE289 (Promega, Madison, WI), and the sequences were confirmed. PSIF was amplified using PSIF primer-1 (5Ј-GATGATC-GATCGCGGCCGCAGGTGCGCCGGTGCCGTATCCGGATCCGCT-GGAACCGCGTGCCGCAGACTACAAAGACGACGACGACAAACC-CGAGGGCGGCAGCCTGGCCGCGCTGACC-3Ј, the underline indicates the NotI site, and the italic letters indicate the FLAG sequence), PSIF primer-2 (5Ј-GATCGATCGATCACTAGTCTACAGTT-CGTCTTTCTTCAGGTCCTCGCGCGGCGGTTTGCCGGG-3Ј, the underline indicates SpeI site), and Pseudomonas aerginosa cDNA as a template. The resulting PCR products were subcloned into the pGEM T-Easy Vector, and the sequences were confirmed. The NotI/SpeI-digested PSIF fragment was inserted into the NotI/SpeIdigested pY02 (Yamamoto et al., 2003) to generate pY02-PSIF. The pTA/C-CPE and pTA/C-CPE289 plasmids were digested with NotI and NcoI, and the fragments were inserted into NotI/NcoI-digested pY02-PSIF to generate pY02-C-CPE-PSIF and pY02-C-CPE289-PSIF. The C-CPE-PSIF plasmids were transduced into Escherichia coli strain TG1, after which the cells were grown at 37°C in 2YT medium (Invitrogen, Carlsbad, CA) containing 2% glucose to an optical density at 600 nm of 0.6 to 0.9. The medium was then changed to 2YT medium containing 1 mM isopropyl ␤-D-thiogalactopyranoside. After an additional 18 h of culture at 30°C, the cells were harvested and centrifuged. The resulting supernatant was applied to anti-FLAG M2 affinity gel, and the bound proteins were eluted with FLAG peptide. The buffer was exchanged with phosphate-buffered saline (PBS) using a PD-10 column (GE Healthcare), and the purified protein was stored at Ϫ80°C until use. Purification of the of C-CPE-PSIF proteins was confirmed by SDS-polyacrylamide gel electrophoresis (PAGE), followed by staining with Coomassie Brilliant Blue and by immunoblotting with anti-FLAG M2 antibody ( Fig. 1 ; data not shown). Protein was quantified using a commercially available assay kit with BSA as a standard (Bio-Rad, Hercules, CA).
Preparation of C-CPE. Following digestion of pTA/C-CPE with XhoI and NotI, the resulting DNA fragments were inserted into XhoI/NotI-digested pGEX4T-1 (GE Healthcare). Glutathione S-transferase-fused C-CPE was prepared as follows. The pGEX4T-1 plasmid encoding C-CPE was transduced into E. coli BL21 (DE3), after which the cells were cultured in LB medium at 37°C until the logarithmic phase. The culture was then adjusted to 1 mM isopropyl ␤-D-thiogalactopyranoside, and the cells were grown for an additional 6 h. The cells were harvested and then solubilized in lysis buffer (10 mM Tris-HCl, 150 mM NaCl, and 1 mM EDTA, pH 8.0) containing 100 g/ml lysozyme, 5 mM dithiothreitol, and 1.5% Nlauroylsarcosine. The lysate was centrifuged, after which the super-natant was collected and adjusted to 2% Triton X-100. The supernatant was incubated with glutathione-agarose beads for 2 h at 4°C. The beads were then washed with the lysis buffer, and C-CPE was eluted from the beads by cleavage with thrombin. Thrombin was removed from the eluted protein using Benzamidine-Sepharose 4 Fast Flow. The buffer was then exchanged with PBS using a PD-10 column. The purification of C-CPE was confirmed by SDS-PAGE (data not shown).
Trypan Blue Assay. Cells were treated with vehicle or C-CPE-PSIF proteins for the indicated periods. Both the floating and adherent cells were recovered and were suspended in ice-cold PBS. The cell suspension was adjusted to 0.2% trypan blue, and the number of stained (dying or dead) and unstained (living) cells was counted. At least 300 cells were counted to determine the fraction of dead cells.
L-Lactate Dehydrogenase Release Assay. The release of lactate dehydrogenase (LDH) from the cells was analyzed using a CytoTox96 NonRadioactive Cytotoxicity Assay kit (Promega) according to the manufacturer's protocol. LDH release was calculated using the following equation: percentage of maximal LDH release ϭ LDH in the cultured medium/total LDH in the culture dish.
Competition Assay. MCF-7 cells were pretreated with C-CPE or BSA at the indicated concentration for 1 h, after which C-CPE-PSIF was added to the cells. After an additional 36 h of culture, LDH release was assayed as described above.
Statistical Analysis. Statistical significance of differences was assessed using one-way analysis of variance followed by Dunnett's test. Differences were considered significant when p Ͻ 0.05.
Results

Preparation of C-CPE-PSIF.
To assess the ability of C-CPE to target claudin-4-expressing cells, we fused it with PSIF. Because of limitations of the restriction sites in the PSIF-encoding plasmid, we linked C-CPE to a site upstream of the 5Ј terminus of PSIF (Fig. 1A) . As shown in Fig. 1B , C-CPE-PSIF was produced effectively by E. coli and could be purified by affinity chromatography using anti-FLAG antibodies. Its molecular size as determined by SDS-PAGE was identical to its predicted size (58 kDa).
Cytotoxic Properties of C-CPE-PSIF. To examine the cytotoxic properties and specificity of C-CPE-PSIF, we compared its effects on L cells, which lack endogenous claudins, and MCF-7 cells, which express endogenous claudin-4 ( Fig.  2A) . Trypan blue dye exclusion showed C-CPE-PSIF caused Fig. 1 . Preparation of C-CPE-PSIF. A, schematic structure of C-CPE-PSIF. C-CPE-PSIF is a fusion of C-CPE and PSIF. The putative receptorbinding region of C-CPE is located in its C terminus and is shown here as the dark area (Hanna et al., 1991) . PSIF contains domains II and III of PE. Domain II is critical for escape of the toxin from the endosome to the cytosol, and domain III is responsible for inhibition of protein synthesis (Ogata et al., 1990) . B, purification of C-CPE-PSIF. C-CPE-PSIF was expressed in E. coli and isolated by anti-FLAG affinity chromatography. The purification of C-CPE-PSIF was confirmed by SDS-PAGE followed by staining with Coomassie Brilliant Blue (CBB) (lanes 1-3) and by immunoblotting using an antibody against FLAG (lane 4). The arrow indicates the purified C-CPE-PSIF. Lane 1, E. coli lysates; lane 2, flow-through; lanes 3 and 4, eluted fraction. 
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at ASPET Journals on July 13, 2017 jpet.aspetjournals.org dose-dependent cell death in MCF-7 cells, with 92% death after a 36-h treatment with 2 g/ml C-CPE-PSIF (Fig. 2B) . Similar results were observed in the LDH release assay. In this case, 8 g/ml C-CPE-PSIF caused the release of approximately 100% of the LDH (Fig. 2C) . In contrast, even at 8 g/ml, C-CPE/PSIF was not cytotoxic to L cells and Caco-2 cells (Fig. 2, B and C) . Taken together, these results suggested that C-CPE-PSIF is toxic to claudin-4-expressing tumor epithelial cells.
Targeting Properties of C-CPE-PSIF. We next used a competition assay to determine whether C-CPE-PSIF binds to MCF-7 cells via C-CPE. As shown in Fig. 3A , pretreatment of the cells with C-CPE dose dependently attenuated the cytotoxic activity of 0.5 g/ml C-CPE-PSIF, with a maximal effect observed at 5 g/ml C-CPE. In contrast, pretreatment of the cells with 10 g/ml BSA did not reduce the cytotoxicity of 0.5 g/ml C-CPE/PSIF. These results suggest that C-CPE-PSIF interacts with MCF-7 cells via the C-CPE domain.
C-CPE is known to bind to claudin-4 via its 30 C-terminal acids . To confirm that claudin-4 is involved in the cytotoxicity of C-CPE-PSIF, we prepared C-CPE289-PSIF, which lacks the claudin-4-binding region of C-CPE. As expected, C-CPE-PSIF had a powerful toxic effect on MCF-7 cells, reaching 70% cell death at 4 g/ml. In contrast, even at 8 g/ml, C-CPE289-PSIF was not cytotoxic. These results suggested that interaction with claudin-4 is essential for the cytotoxicity of C-CPE-PSIF.
To confirm this possibility, we evaluated the cytotoxic activity of C-CPE-PSIF in L cells expressing claudin-1 (CL1/L cells), -2 (CL2/L cells), -4 (CL4/L cells), and -5 (CL5/L cells) (Figs. 4, B and C) . C-CPE-PSIF was not cytotoxic in CL1/L, CL2/L, and CL5/L cells (Fig. 4C) , and it was toxic in CL4/L cells (31.3 and 73.5% LDH release at 0.1 and 5 g/ml, respectively). These results confirm that the C-CPE domain of C-CPE-PSIF interacts with claudin-4 on the cell membrane.
Discussion
In the current studies, we found that a C-CPE-PSIF fusion protein is potently cytotoxic to claudin-4-expressing cells. This suggests that C-CPE could be used to confer claudin binding to drugs.
We used a fusion in which the C terminus of C-CPE was linked to the N terminus of PSIF. Thus, the receptor-binding region of C-CPE may be influenced by fusion with PSIF. To investigate this further, we are currently attempting to prepare C-CPE-PSIF with a G4S linker inserted between the C-CPE and PSIF domains. In the current studies, it was necessary to connect PSIF to the C terminus of C-CPE be- cause of technical aspects of plasmid construction, and we need to consider the function of C-CPE when preparing other claudin-4-targeting molecules. Solution of the three-dimensional structures of claudins and CPE should be helpful. Competitive analysis using C-CPE revealed that C-CPE-PSIF interacted with cells via the C-CPE domain. Thus, cellular uptake of C-CPE-PSIF appears to be dependent on the interaction of claudin-4 with C-CPE. Indeed, we found that L cells expressing claudin-1, -2, or -5 are insensitive to C-CPE-PSIF and that deletion of the claudin-4-binding domain of C-CPE eliminates its cytotoxicity. These results indicate that C-CPE-PSIF binds to claudin-4 on the cell surface. Similarly, Fujita et al. (2000) showed that CPE binds to claudin-4 but not claudin-1, -2, or -5. Also, expression of claudin-4 but not -1 or -5 confers sensitivity to CPE (Sonoda et al., 1999; Fujita et al., 2000) . Thus, our data are consistent with previous findings, and they show that fusion with C-CPE, the receptor-binding region of CPE, confers claudin binding to PSIF. The receptor-binding region of CPE was previously narrowed to the C-terminal 30 amino acids (Hanna et al., 1991) . Similarly, we reported that deletion of the C-terminal 30 amino acids of C-CPE eliminates its ability to bind claudin-4 . Here, we showed that deletion of the 30 amino acids in C-CPE-PSIF abolishes its toxic effects. Taken together, the results indicate that C-CPE could be used to target drugs to claudin-4.
For the use of claudins as targets for drug delivery, it is important to understand whether molecules binding to claudin on the cell surface are taken up into the cells. PSIF is a useful as a reporter for screening ligands (Siegall et al., 1990; Theuer et al., 1992; Leamon et al., 1993) . Because C-CPE-PSIF was cytotoxic in claudin-4-expressing cells, we expect that C-CPE-PSIF must enter the cytosol. This leaves the question of how C-CPE-PSIF enters the cells. One possibility is that it is taken up by endocytosis, after which it escapes from the endosomes into the cytosol. Generally, proteins are targeted to clathrin-coated vesicles by a sorting signal sequence, including YXXØ or EXXXLL (where X is any amino acid, and Ø is a bulky hydrophobic residue) (Bonifacino and Traub, 2003) . Because claudin-4 contains an ALGVLL motif at amino acids 92 to 97 and a YVGW motif at amino acids 165 to 168 (Ivanov et al., 2004) , it may be taken up by clathrinmediated endocytosis. Indeed, Matsuda et al. (2004) showed that the endocytosis of claudins occurs during the remodeling of TJs.
Claudins are overexpressed in some tumor cells. Administration of CPE has been shown to reduce the growth of claudin-4-overexpressing human ovarian and pancreatic tumors (Michl et al., 2001; Rangel et al., 2003; Santin et al., 2005) . CPE contains not only a claudin-4-binding domain but also a cytotoxic domain (McClane and Chakrabarti, 2004) . Therefore, it is hard to use CPE in itself as a targeting molecule to claudin-4. Offner et al. (2005) reported that antibodies for claudins bind to claudin-expressing carcinomas, suggesting that anti-claudin antibodies or their F v domains could be used to target antitumor agents to claudin-positive tumors. However, targeting of an antitumor agent to cells via a claudin has never been achieved. In this point, C-CPE is a useful claudin-4-targeting molecule, and C-CPE could target not only antitumor agents but also liposomes to claudin-4-overexpressing tumor cells. Although claudin-4 is also distributed in normal tissues such as normal colon epithelium and several glands, the expression in normal tissues is weaker than in tumors (Long et al., 2001; Michl and Gress, 2004) . Therefore, detailed analysis for mechanism of interaction between C-CPE and claudin-4 is needed for a future application of antitumor therapy using C-CPE. In the present study, we found that C-CPE-PSIF was nontoxic in Caco-2 cells. We previously reported that addition of C-CPE in basal side not apical side of Caco-2 monolayer resulted in decrease of the barrier function of TJ Takahashi et al., 2005) . McClane and Chakrabarti (2004) also reported that Caco-2 cells are more sensitive to CPE when CPE is applied to their basal side than when CPE is applied to their apical sides. Taken together, insensitivity of Caco-2 cells to C-CPE-PSIF may be due to polarization of Caco-2 cells. This is an interesting founding, and it is an important issue to clarify the relationship between sensitivity of C-CPE-PSIF and polarization of claudin-4 in tumor tissues and normal tissues. C-CPE reduced the barrier function of TJ of epithelia , and utilization of C-CPE may facilitate drug delivery to intratumor tissues.
We previously showed that the C-terminal 16 amino acids of C-CPE are responsible for its interaction of claudin-4 ( Kondoh et al., 2005) , indicating that modification of the C terminus of C-CPE could allow other claudins to be targeted. For example, it may be useful to target claudin-10 because it is overexpressed in hepatocellular carcinomas (Cheung et al., 2005) . Because the plasmid encoding C-CPE-PSIF is a phagemid vector, its binding specificity can be easily manipulated using phage display. We are currently attempting to identify the precise claudin-4 binding region of C-CPE and to use a phage display library to prepare versions of C-CPE that can bind other claudins.
In summary, we showed that the C-CPE domain of C-CPE-PSIF targets claudin-4. This is the first report that C-CPE can allow the targeting of a drug to claudin-4. Because of these results, we are currently developing a claudin-targeting drug delivery system.
